Top

24-04-2024 | COVID-19 | Observational Research

Antineutrophil cytoplasmic antibody positivity incidence before and during COVID-19 pandemic

Authors: Perković Dijana, Petrić Marin, Petra Šimac, Vodanović Ana, Borić Katarina, Gugo Katarina, Tandara Leida

Published in: Rheumatology International

Excerpt

There are many factors associated with the development of autoimmune diseases. It is known that viral infections can be the triggers of these diseases [1, 2]. Since the end of 2019, the world has been faced with the global COVID19 pandemic caused by coronavirus 2 (SARS-CoV-2). As knowledge about the virus and its broad pathogenetic potential increased, evidence emerged of the development of various autoantibodies and autoimmune diseases following COVID19 infections [3‐5]. COVID-19 was associated with a polyclonal autoreactive B cell activation reflected by an increased number of plasma autoantibody levels [3]. Molecular mimicry together with hyperactivity of the host’s immune system during the infection of COVID19 are some of the possible mechanisms for the induction of autoimmunity [6]. One of the important features of the COVID-19 infection is elevated neutrophil-to-lymphocyte ratio and elevated neutrophil extracellular trap (NET) circulation. NETs, on the other hand, can further activate complement pathways causing tissue destruction and vasculitis [7]. …

Hussein HM, Rahal EA (2019) The role of viral infections in the development of autoimmune diseases. Crit Rev Microbiol 45(4):394–412. https://doi.org/10.1080/1040841X.2019.1614904CrossRefPubMed

Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM (2019) Viruses and autoimmunity: a review on the potential Interaction and Molecular mechanisms. Viruses 11(8):762. https://doi.org/10.3390/v11080762CrossRefPubMedPubMedCentral

Jiang W, Johnson D, Adekunle R et al (2023) COVID-19 is associated with bystander polyclonal autoreactive B cell activation as reflected by a broad autoantibody production, but none is linked to disease severity. J Med Virol 95(1):e28134. https://doi.org/10.1002/jmv.28134CrossRefPubMed

Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y (2021) The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 20(4):102792. https://doi.org/10.1016/j.autrev.2021.102792CrossRefPubMedPubMedCentral

Yazdanpanah N, Rezaei N (2022) Autoimmune complications of COVID-19. J Med Virol 94(1):54–62. https://doi.org/10.1002/jmv.27292CrossRefPubMed

Vahabi M, Ghazanfari T, Sepehrnia S (2022) Molecular mimicry, hyperactive immune system, and SARS-COV-2 are three prerequisites of the autoimmune disease triangle following COVID-19 infection. Int Immunopharmacol 112:109183. https://doi.org/10.1016/j.intimp.2022.109183CrossRefPubMedPubMedCentral

Ozcan S, Sonmez O, Karaca C, Ozdede A, Seyahi N (2022) ANCA-associated vasculitis flare might be provoked by COVID-19 infection: a case report and a review of the literature. Clin Kidney J 15(11):1987–1995. https://doi.org/10.1093/ckj/sfac186CrossRefPubMedPubMedCentral

Ackermann M, Anders HJ, Bilyy R et al (2021) Patients with COVID-19: in the dark-NETs of neutrophils. Cell Death Differ 28(11):3125–3139. https://doi.org/10.1038/s41418-021-00805-zCrossRefPubMedPubMedCentral

Narasaraju T, Tang BM, Herrmann M, Muller S, Chow VTK, Radic M (2020) Neutrophilia and NETopathy as key pathologic drivers of progressive lung impairment in patients with COVID-19. Front Pharmacol 11:870. https://doi.org/10.3389/fphar.2020.00870CrossRefPubMedPubMedCentral

10.

Villacorta J, Diaz-Crespo F, Acevedo M, Guerrero C, Mollejo M, Fernandez-Juarez G (2016) Antineutrophil cytoplasmic antibody negative pauci-immune extracapillary glomerulonephritis. Nephrol (Carlton) 21(4):301–307. https://doi.org/10.1111/nep.12608CrossRef

11.

Domínguez-Quintana M, Alba MA, Hinojosa-Azaola A (2021) Classification of ANCA-associated vasculitis: differences based on ANCA specificity and clinicopathologic phenotype. Rheumatol Int 41(10):1717–1728. https://doi.org/10.1007/s00296-021-04966-5CrossRefPubMed

12.

Kitching AR, Anders HJ, Basu N et al (2020) ANCA-associated vasculitis. Nat Rev Dis Primers 6(1):71. https://doi.org/10.1038/s41572-020-0204-yCrossRefPubMed

13.

Izci Duran T, Turkmen E, Dilek M, Sayarlioglu H, Arik N (2021) ANCA-associated vasculitis after COVID-19. Rheumatol Int 41(8):1523–1529. https://doi.org/10.1007/s00296-021-04914-3CrossRefPubMedPubMedCentral

14.

Morris D, Patel K, Rahimi O, Sanyurah O, Iardino A, Khan N (2021) ANCA Vasculitis: a manifestation of post-covid-19 syndrome. Respir Med Case Rep 34:101549. https://doi.org/10.1016/j.rmcr.2021.101549CrossRefPubMedPubMedCentral

15.

Allena N, Patel J, Nader G, Patel M, Medvedovsky B (2021) A rare case of SARS-CoV-2-Induced microscopic polyangiitis. Cureus 13(5):e15259. https://doi.org/10.7759/cureus.15259CrossRefPubMedPubMedCentral

16.

Chandok T, Nasr R, Uday KA (2023) A case of Antineutrophil cytoplasmic antibody Vasculitis-Associated Acute kidney Injury in a patient with asymptomatic COVID-19 infection. Cureus 15(2):e35006. https://doi.org/10.7759/cureus.35006CrossRefPubMedPubMedCentral

17.

Kitamoto K, Tanaka Y, Kuboyama T et al (2023) Newly diagnosed ANCA-associated vasculitis after COVID-19 infection: a case report. J Med Case Rep 17(1):366. https://doi.org/10.1186/s13256-023-04081-yCrossRefPubMedPubMedCentral

18.

Giollo A, Bixio R, Gatti D et al (2023) Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: a missed ‘window of opportunity’. Ann Rheum Dis 82(8):e181. https://doi.org/10.1136/annrheumdis-2020-218830CrossRefPubMed

19.

Kakoullis L, Parperis K, Papachristodoulou E, Panos G (2020) Infection-induced myeloperoxidase specific antineutrophil cytoplasmic antibody (MPO-ANCA) associated vasculitis: a systematic review. Clin Immunol 220:108595. https://doi.org/10.1016/j.clim.2020.108595CrossRefPubMed

20.

Basic-Jukic N, Pavlisa G, Sremec NT et al (2023) Autoantibodies in COVID-19, a possible role in the pathogenesis of the disease. Ther Apher Dial 27(5):882–889. https://doi.org/10.1111/1744-9987.14004CrossRefPubMed

21.

Sato T, Umeda M, Sato S et al (2023) Increase in the number of new cases of ANCA-associated vasculitis in the COVID-19 vaccine era. Clin Immunol 252:109656. https://doi.org/10.1016/j.clim.2023.109656CrossRefPubMedPubMedCentral

22.

Kadkhoda K, Laurita K (2021) Antineutrophil cytoplasmic antibodies and their association with clinical outcomes in hospitalized COVID-19 patients. Cell Death Discov 7(1):277. https://doi.org/10.1038/s41420-021-00671-1CrossRefPubMedPubMedCentral

23.

Hilhorst M, van Paassen P, Tervaert JW (2015) Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis. J Am Soc Nephrol 26(10):2314–2327. https://doi.org/10.1681/ASN.2014090903CrossRefPubMedPubMedCentral

24.

Yang JJ, Preston GA, Pendergraft WF et al (2001) Internalization of proteinase 3 is concomitant with endothelial cell apoptosis and internalization of myeloperoxidase with generation of intracellular oxidants. Am J Pathol 158(2):581–592. https://doi.org/10.1016/S0002-9440(10)64000-XCrossRefPubMedPubMedCentral

25.

Xiao H, Hu P, Falk RJ, Jennette JC (2016) Overview of the pathogenesis of ANCA-Associated Vasculitis. Kidney Dis (Basel) 1(4):205–215. https://doi.org/10.1159/000442323CrossRefPubMed

26.

Preston GA, Pendergraft WF 3rd, Falk RJ (2005) New insights that link microbes with the generation of antineutrophil cytoplasmic autoantibodies: the theory of autoantigen complementarity. Curr Opin Nephrol Hypertens 14(3):217–222. https://doi.org/10.1097/01.mnh.0000165886.93427.b1CrossRefPubMed

27.

Frisardi V, Brunetti O, Abbinante V et al (2023) Impact of COVID-19 pandemic on outpatient visit volume in cancer patients: results of COMETA multicenter retrospective observational study. Front Public Health 11:1077103. https://doi.org/10.3389/fpubh.2023.1077103CrossRefPubMedPubMedCentral

28.

Auanassova A, Yessirkepov M, Zimba O et al (2023) Physicians’ perceptions about antineutrophil cytoplasmic antibody-associated vasculitis: an online survey report in the time of the COVID-19 pandemic. Clin Rheumatol 42(3):831–837. https://doi.org/10.1007/s10067-022-06452-0CrossRefPubMed

29.

Brolin S, Welin E, Lövström B, Bruchfeld A, Gunnarsson I, Pettersson S (2022) Exploring the educational needs of patients with systemic vasculitis using the educational needs assessment tool. Rheumatol Adv Pract 6(2):rkac062. https://doi.org/10.1093/rap/rkac062CrossRefPubMedPubMedCentral

Title: Antineutrophil cytoplasmic antibody positivity incidence before and during COVID-19 pandemic
Authors: Perković Dijana
Petrić Marin
Petra Šimac
Vodanović Ana
Borić Katarina
Gugo Katarina
Tandara Leida
Publication date: 24-04-2024
Publisher: Springer Berlin Heidelberg
Keywords: COVID-19
Vasculitis
Vasculitis
Published in: Rheumatology International
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-024-05596-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials